While still a giant, many investors now prefer the XBI (SPDR S&P Biotech) for its equal-weight approach to smaller, high-growth companies. 3. Short-Term Treasury & Cash (The Safety Net)
As rates rose, "cash-like" ETFs finally started providing a modest yield without the drama of the stock market. Review Summary: Was 2018 a good year to buy? 2018 Context Long-term Verdict Broad Market (VOO/VTI) Rough end to the year (-4% approx). best etf to buy 2018
Buying the 2018 dip led to massive gains in 2019-2021. Tech (QQQ) Volatile, but stayed flat/positive. Winner. The dominant theme of the last decade. Dividends (VYM) Struggled due to rising rates. Moderate. Better for income than raw growth. The "Best" Pick in Hindsight While still a giant, many investors now prefer
Strong M&A (mergers and acquisitions) activity kept this fund in the green while other sectors slumped. Review Summary: Was 2018 a good year to buy
As of , we can evaluate these 2018 picks with the benefit of hindsight to see which ones stood the test of time. Top ETF Categories of 2018
2018 was a volatile year for the market, characterized by trade tensions and rising interest rates. The "best" ETFs that year generally fell into three categories:
Healthcare often acts as a "defensive" sector during volatility. In 2018, breakthroughs in gene therapy boosted specific biotech ETFs. iShares Nasdaq Biotechnology ETF (IBB)